Amgen (AMGN) Gross Profit Growth (3y) (2012 - 2026)

Amgen (AMGN) Gross Profit Growth (3y) (2012 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Profit Growth (3y) (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 44.89%
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 3.95%
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 9.39%
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 12.01%
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn 4.61%
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 10.24%
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 3.66%
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 1.34%
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn 0.31%

Historic Data

Download Data
DateValue
Mar 31, 2026 10.24%
Dec 31, 2025 150.27%
Sep 30, 2025 8.54%
Jun 30, 2025 21.43%
Mar 31, 2025 3.47%
Dec 31, 2024 -19.35%
Sep 30, 2024 18.27%
Jun 30, 2024 1.76%
Mar 31, 2024 18.51%
Dec 31, 2023 2.38%
Sep 30, 2023 -7.41%
Jun 30, 2023 3.12%
Mar 31, 2023 -1.92%
Dec 31, 2022 -31.58%
Sep 30, 2022 4.58%
Jun 30, 2022 3.68%
Mar 31, 2022 -3.98%
Dec 31, 2021 23.88%
Sep 30, 2021 -0.57%
Jun 30, 2021 -4.76%